Exabis Library
Welcome to the e-CCO Library!
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P332: Influence of mesalamine maintenance therapy on progression of ulcerative proctitis in Korea
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P332: Multinational comparisons of practices in overseas travel in Crohn’s disease and ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P332: Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P332: Treat to target in Crohn's disease: ultrasonographic response is associated with better outcomes
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P333 Biologic longevity: Withdrawal of drugs due to remission is rare in clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P333: Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P333: Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P333: Early intestinal ultrasound remission is associated with endoscopic healing after one year of infliximab therapy in Crohn's disease: a multicentre prospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P333: Endoscopic severity and CRP predict failure of medical rescue therapy in patients with acute severe ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P333: Long-term efficacy and safety of thiopurines in patients with steroid-dependent ulcerative colitis: a retrospective investigation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P333: The baseline features of patients with newly diagnosed moderate-to-severe ulcerative colitis in Korea: A population-based cohort study (the MOSAIK cohort)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P334: Chromoendoscopy is superior to white light endoscopy for the detection of advanced colonic neoplasia in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P334: Does the circadian clock have a role in the pathogenesis of inflammatory bowel disease (IBD)?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P334: Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P334: Evolution of a long-term follow-up cohort of Crohn’s disease with complex perianal fistula: from antibiotic to combined AZA and anti-TNF based treatment ending up clinical and radiological healing with or without stoma
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P334: Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P334: Respiratory Manifestations and Association Between Disease Activity in Patients with Inflammatory Bowel Disease in a Reference Center in Salvador, Bahia, Brazil.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM